149 related articles for article (PubMed ID: 26238770)
1. Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.
Kikkert WJ; van Brussel PM; Damman P; Claessen BE; van Straalen JP; Vis MM; Baan J; Koch KT; Peters RJ; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
J Thromb Thrombolysis; 2016 Apr; 41(3):441-51. PubMed ID: 26238770
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
Kikkert WJ; van Nes SH; Lieve KV; Dangas GD; van Straalen J; Vis M; Baan J; Koch KT; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
Thromb Haemost; 2013 May; 109(5):961-70. PubMed ID: 23446910
[TBL] [Abstract][Full Text] [Related]
3. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
[TBL] [Abstract][Full Text] [Related]
4. Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.
Faulkenberg KD; Beavers JC; Finks SW
Ann Pharmacother; 2016 Feb; 50(2):141-51. PubMed ID: 26681442
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention.
Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C
Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
Rozenman Y; Mehran R; Witzenbichler B; Dangas G; Desaga M; Kochman J; Nilsen DW; Finkelstein A; Mosseri M; Stone GW
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E9-14. PubMed ID: 22511592
[TBL] [Abstract][Full Text] [Related]
7. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
[TBL] [Abstract][Full Text] [Related]
8. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
[TBL] [Abstract][Full Text] [Related]
9. Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter?
Giralt T; Ribas N; Freixa X; Sabaté M; Caldentey G; Tizón-Marcos H; Carrillo X; García-Picart J; Lidón RM; Cárdenas M; Pérez-Fernández S; Mauri J; Vaquerizo B
Int J Cardiol; 2021 Feb; 325():9-15. PubMed ID: 32991944
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
French JK; Edmond JJ; Gao W; White HD; Eikelboom JW
Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722
[TBL] [Abstract][Full Text] [Related]
11. Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial.
Ducrocq G; Jolly S; Mehta SR; Rao SV; Patel T; Moreno R; Gao P; Steg PG
Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25873729
[TBL] [Abstract][Full Text] [Related]
12. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
[TBL] [Abstract][Full Text] [Related]
13. Periprocedural Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction.
Rashid MK; Singh K; Bernick J; Wells GA; Hibbert B; Russo J; So DY; Le May MR;
J Invasive Cardiol; 2019 Dec; 31(12):E387-E391. PubMed ID: 31786531
[TBL] [Abstract][Full Text] [Related]
14. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
[TBL] [Abstract][Full Text] [Related]
15. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
[TBL] [Abstract][Full Text] [Related]
16. The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention.
d'Entremont MA; Laferrière C; Bérubé S; Couture ÉL; Lepage S; Huynh T; Verreault-Julien L; Karzon A; Desgagnés N; Nguyen M
Catheter Cardiovasc Interv; 2021 Mar; 97(4):591-599. PubMed ID: 32860646
[TBL] [Abstract][Full Text] [Related]
17. Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Thomas MP; Mahaffey KW; Chiswell K; Cohen M; Kontos MC; Antman EM; Ferguson JJ; Califf RM; Goodman SG; Becker RC
J Thromb Thrombolysis; 2012 Jul; 34(1):114-9. PubMed ID: 22323092
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
[TBL] [Abstract][Full Text] [Related]
19. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
20. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
